Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H2 2017

Date: October 31, 2017
Pages: 162
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: B183623FADFEN
Leaflet:

Download PDF Leaflet

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H2 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H2 2017, provides an overview of the Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) pipeline landscape.

Basal cell carcinoma is a type of skin cancer which begins in the basal cells. Symptoms include waxy bump, scaly, brown or flesh-colored patch and white, waxy scar. Predisposing factors include age, family history, and exposure to radiation and immunosuppressant medications. Treatment includes chemotherapy and surgery.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 7, 5 and 6 respectively.

Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


NOTE: Out of security concerns Global Markets Direct requires using corporate email address.
Introduction
Global Markets Direct Report Coverage
Basal Cell Carcinoma (Basal Cell Epithelioma) - Overview
Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Basal Cell Carcinoma (Basal Cell Epithelioma) - Companies Involved in Therapeutics Development
Adgero Biopharmaceuticals Holdings Inc
Biofrontera AG
Biosceptre International Ltd
BLR Bio LLC
Cannabis Science Inc
Genextra Spa
Ignyta Inc
Laboratories Ojer Pharma SL
MediGene AG
Medivir AB
Merck & Co Inc
Provectus Biopharmaceuticals Inc
Redx Pharma Plc
Regeneron Pharmaceuticals Inc
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Transgene SA
Basal Cell Carcinoma (Basal Cell Epithelioma) - Drug Profiles
aminolevulinic acid hydrochloride - Drug Profile
aminolevulinic acid hydrochloride - Drug Profile
BIL-010t - Drug Profile
BLR-300 - Drug Profile
cemiplimab - Drug Profile
CS-S/BCC-1 - Drug Profile
DAC-060 - Drug Profile
fluorouracil - Drug Profile
imiquimod SR - Drug Profile
Oshadi D + Oshadi R - Drug Profile
patidegib hydrochloride - Drug Profile
pembrolizumab - Drug Profile
PV-10 - Drug Profile
RDX-001 - Drug Profile
remetinostat - Drug Profile
rostaporfin - Drug Profile
SBT-300 - Drug Profile
sinecatechins - Drug Profile
taladegib - Drug Profile
TG-1042 - Drug Profile
tigilanol tiglate - Drug Profile
Basal Cell Carcinoma (Basal Cell Epithelioma) - Dormant Projects
Basal Cell Carcinoma (Basal Cell Epithelioma) - Discontinued Products
Basal Cell Carcinoma (Basal Cell Epithelioma) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Adgero Biopharmaceuticals Holdings Inc, H2 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Biofrontera AG, H2 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Biosceptre International Ltd, H2 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by BLR Bio LLC, H2 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Cannabis Science Inc, H2 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Genextra Spa, H2 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Ignyta Inc, H2 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Laboratories Ojer Pharma SL, H2 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by MediGene AG, H2 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Medivir AB, H2 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Merck & Co Inc, H2 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Provectus Biopharmaceuticals Inc, H2 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Redx Pharma Plc, H2 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Regeneron Pharmaceuticals Inc, H2 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H2 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Transgene SA, H2 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Dormant Projects, H2 2017
Basal Cell Carcinoma (Basal Cell Epithelioma) - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

COMPANIES MENTIONED

Adgero Biopharmaceuticals Holdings Inc
Biofrontera AG
Biosceptre International Ltd
BLR Bio LLC
Cannabis Science Inc
Genextra Spa
Ignyta Inc
Laboratories Ojer Pharma SL
MediGene AG
Medivir AB
Merck & Co Inc
Provectus Biopharmaceuticals Inc
Redx Pharma Plc
Regeneron Pharmaceuticals Inc
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Transgene SA
Skip to top


Ask Your Question

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: